2023 PDA Letter Article of the Year
Every year, scientists submit their articles for consideration in the PDA Letter. Then, at the end of the year, the PDA Letter and the Editorial Committee identify the top articles published based on reader interest and select the one that best encapsulates PDA’s mission of connecting People, Science and Regulation®.
The award is given to the author(s) at the Awards Ceremony that is held at PDA’s recurring Annual Meeting. With that being said, the 2023 honorary award for the article of the year was awarded to Federic Ayers article titled How to Establish Effective CCS with TR-90 | PDA. In the article, the Ayers illustrates how the published Technical Report No. 90: Contamination Control Strategy Development helps companies establish an effective contamination control strategy by demonstrating a combination of these linked elements: foundation, contamination control, validation of controls, monitoring of controls and governance.
With the five elements above, Ayers states, “Creating a sturdy CCS will allow an organization to assess and continuously improve its level of contamination control, which can reduce manufacturing losses and better attend to the patients the industry serves.”
Moreover, PDA congratulates Ayers on receiving the 2023 Article of the Year Award! We appreciate him for sharing his knowledge to help improve and maintain high-quality standards in the industry. Thank you!
Year | Title | Author |
---|---|---|
2023 | “How to Establish Effective CCS with TR-90” | Frederic Ayers, Eli Lilly and Company |
2022 | “Zero Defect – A Competitive Advantage” | Ruby Gulati and Snehal Parikh, Roche-Genentech |
2021 | “The Modern Quality Professional Development Tool, Parts I, II & III” | Stephan Krause, PhD; Mariam Khan; Callum Chapman; Rob Gaglione; Andy Spasoff; Anthony Mire-Sluis, AstraZeneca |
2020 | “Industry Must Move Away from Dye Ingress Test” | Oliver Stauffer, PTI – Packaging Technologies & Inspection |
2019 | “Lifecycle Approach Wipes Away Cleaning Validation Concerns” | Rajyalashmi Vathyam, Takeda Pharmaceutical Company |